Clinical Quality Assurance (CQA)

Clinical quality assurance (CQA) provides independent oversight so clinical trials meet FDA regulations, ICH GCP, and sponsor quality standards. CQA looks beyond monitoring visit checklists to how TMF completeness, protocol adherence, safety reporting, and vendor performance hold up under audit or inspection. Viltis consultants support study-level and program-level quality oversight that protects subjects and the reliability of the clinical data package used in regulatory submissions.

Effective CQA starts early. Protocol design, informed consent processes, vendor selection, and system setup for EDC or eTMF all create quality risk before first patient in. During conduct, audits of sites, CROs, and core processes surface issues while correction is still possible. Closeout work confirms that unresolved CAPAs, missing essential documents, and data queries do not linger into submission or inspection windows when timelines are already tight and teams are stretched.

CQA deliverables should be usable by clinical operations, not just archived. Audit reports need clear severity language, CAPA owners, and due dates tied to risk. SOP gaps identified in audits should feed controlled document updates and retraining so the same finding does not reappear at the next site. Our consultants help sponsors build risk-based audit plans, execute GCP audits, and coach teams on inspection interview habits that stay factual under pressure.

Viltis offers CQA consulting and embedded quality resources for sponsors and partners. We do not issue regulatory certificates or replace the sponsor's ultimate responsibility for trial quality and regulatory submissions. Support is designed to fit your QMS, SOPs, and governance model so findings lead to durable process fixes rather than one-off document cleanup in the weeks before a filing, partner audit, or FDA inspection.

Clinical quality assurance activities commonly include

• GCP audits of sites, CROs, and clinical processes
• Study and program quality oversight planning
• TMF and essential document quality reviews
• Vendor qualification and performance audit support
• CAPA development, tracking, and effectiveness checks
• Inspection readiness coaching for clinical teams

If your portfolio has grown faster than quality capacity, or a recent audit exposed weak CAPA follow-through, focused CQA support can restore control before the next FDA inspection. Contact Viltis today to discuss study or program priorities and where independent GCP oversight would help most right now.